Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunovant, Inc. - Common Stock
(NQ:
IMVT
)
14.56
+0.26 (+1.82%)
Streaming Delayed Price
Updated: 10:04 AM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunovant, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 21, 2023
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Via
Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
December 21, 2023
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.
Via
Investor's Business Daily
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
December 21, 2023
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in
Via
Benzinga
Argenx Dives On Autoimmune Therapy Failure
December 20, 2023
A treatment for a skin-blistering condition failed to beat a placebo.
Via
Investor's Business Daily
Analyst Ratings for Immunovant
December 01, 2023
Via
Benzinga
Where Immunovant Stands With Analysts
November 15, 2023
Via
Benzinga
Recap: Immunovant Q2 Earnings
November 09, 2023
Via
Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
December 21, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
December 21, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From
Roivant Sciences
Via
GlobeNewswire
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 20, 2023
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.
Via
Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023
From
Roivant Sciences
Via
GlobeNewswire
The Latest Analyst Ratings for Immunovant
October 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
October 13, 2023
Via
Benzinga
Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday
October 05, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
September 29, 2023
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.
Via
Investor's Business Daily
What's Going On Pfizer's Subsidiary Biohaven Stock?
September 27, 2023
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an
Via
Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 27, 2023
Gainers
Via
Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
September 27, 2023
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.
Via
Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
September 27, 2023
The company may have best-in-class autoimmune disease therapy under its roof.
Via
The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
September 27, 2023
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
September 27, 2023
Via
Benzinga
MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
September 27, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
September 27, 2023
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion.
Via
Talk Markets
Why Shares of Immunovant Are Soaring on Tuesday
September 26, 2023
Immunovant sees strong potential for an autoimmune disorder therapy.
Via
The Motley Fool
Nasdaq Down 1.5%; Immunovant Shares Spike Higher
September 26, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday. The Dow traded down 1.19% to 33,601.60 while the NASDAQ fell 1.48% to 13,074.97. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 26, 2023
Via
Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 26, 2023
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.